A Phase 2 interventional study of Phentolamine Mesylate (NV-101) in Anesthesia, Dental, sponsored by Novalar Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2006-11-17.
Sponsored by Novalar Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Hypesthesia with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Hypesthesia · United States.
Among the 20 studies in Hypesthesia with a site in United States, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 2nd registered.
47 studies on the registry are indexed under Hypesthesia; 12 are open to participants now.
Browse Hypesthesia studies →2 of the 20 studies in Hypesthesia with a site in United States are open now. Recruiting first, the newest first:
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+ · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Hypesthesia studies recruiting now, 7 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 50 across 43 interventional studies indexed under Hypesthesia.
Median enrollment 72 across the 18 interventional studies, 218 across the 2 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
Novalar Pharmaceuticals, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Novalar Pharmaceuticals, Inc. has 4 studies filed under Hypesthesia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Hypesthesia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the safety and efficacy of NV-101 in approximately 150 children 4 to 11 years of age. NV-101 or sham injection is administered at the completion of a dental procedure requiring local anesthesia with 2% lidocaine with 1:100,000 epinephrine. The dental procedure(s) shall be performed in a single quadrant of the mouth and include cavity preparation, restoration/filling, teeth cleaning (non-surgical scaling and/or root planing), or crowns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects 6 to 11 years of age who are trainable in standardized palpation procedure:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(All subjects) to evaluate the safety and tolerability of NV-101 as measured by: incidence, severity of adverse events
incidence, severity and duration of intraoral pain as measured by Wong Baker Pain Rating Scale
clinically significant changes in vital signs
clinically significant changes in oral cavity assessments
analgesics required for intraoral pain
(For subjects 6 to 11 years of age who are trainable in standardized palpation procedure): to determine if NV-101 accelerates the time to normal tongue sensation as measured by standardized palpation procedure
for mandibular procedures, to determine if NV-101 accelerates the time to normal tongue sensation as measured by standardized palpation procedure
The record gives a start of Mar 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phentolamine
Novalar Pharmaceuticals, Inc.